8.23

7.86% +0.60

After Hours: 8.23

Vir Biotechnology Inc (VIR)

Overview News Price History Option Chain Why VIR Down? Discussions Forecast

Vir Biotechnology Inc stock is currently priced at $8.23, with a 24-hour trading volume of 1.10M. It has seen a +7.86% increased in the last 24 hours and a -17.45% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $7.75 pivot point. If it approaches the $8.27 resistance level, significant changes may occur.

Previous Close:

$7.63

Open:

$7.74

24h Volume:

1.10M

Market Cap:

$1.10B

Revenue:

$39.49M

Net Income/Loss:

$-615.06M

P/E Ratio:

-1.833

EPS:

-4.49

Net Cash Flow:

$-800.36M

1W Performance:

+3.52%

1M Performance:

-17.45%

6M Performance:

+1.48%

1Y Performance:

-66.34%

1D Range:

$7.64

$8.275

52W Range:

$7.61

$27.48

Vir Biotechnology Inc Stock (VIR) Company Profile

Name

Vir Biotechnology Inc

Sector

Healthcare (1199)

Industry

Biotechnology (688)

Phone

415-906-4324

Address

499 Illinois Street, Suite 500, San Francisco, CA

Employee

237

Twitter

@Vir_Biotech

Next Earnings Date

2024-05-02

Latest SEC Filings

VIR's Discussions on Twitter

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-29-24	Downgrade	JP Morgan	Overweight → Neutral
Sep-08-23	Downgrade	BofA Securities	Buy → Neutral
Mar-06-23	Upgrade	JP Morgan	Neutral → Overweight
Feb-21-23	Upgrade	Goldman	Neutral → Buy
Jan-27-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Sep-14-22	Initiated	SVB Leerink	Outperform
Sep-09-22	Initiated	Morgan Stanley	Underweight
Mar-03-22	Upgrade	Robert W. Baird	Underperform → Neutral
Dec-21-21	Downgrade	Robert W. Baird	Neutral → Underperform
Oct-25-21	Upgrade	JP Morgan	Underweight → Neutral
Sep-22-21	Downgrade	Goldman	Buy → Neutral
Jun-04-21	Resumed	Robert W. Baird	Neutral
Jan-27-21	Downgrade	JP Morgan	Neutral → Underweight
Jan-20-21	Reiterated	H.C. Wainwright	Buy
Oct-05-20	Initiated	BofA Securities	Buy
Sep-14-20	Upgrade	Goldman	Neutral → Buy
Sep-11-20	Upgrade	JP Morgan	Underweight → Neutral
Aug-20-20	Initiated	Needham	Buy
Mar-19-20	Downgrade	JP Morgan	Neutral → Underweight
Mar-13-20	Downgrade	Goldman	Buy → Neutral
Feb-27-20	Downgrade	Robert W. Baird	Neutral → Underperform
Feb-04-20	Downgrade	JP Morgan	Overweight → Neutral
Nov-14-19	Initiated	Robert W. Baird	Neutral
Nov-05-19	Initiated	Barclays	Overweight
Nov-05-19	Initiated	Cowen	Outperform
Nov-05-19	Initiated	Goldman	Buy
Nov-05-19	Initiated	JP Morgan	Overweight

View All

Vir Biotechnology Inc Stock (VIR) Latest News

What Makes Vir Biotechnology (VIR) a New Buy Stock

Zacks Investment Research

Assessing Vir Biotechnology: Insights From 5 Financial Analysts

Benzinga

Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga

Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday

Benzinga

Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 186.41%: Here's is How to Trade

Zacks Investment Research

Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research

Vir Biotechnology Inc Stock (VIR) Financials Data

Vir Biotechnology Inc (VIR) Revenue 2024

VIR reported a revenue (TTM) of $39.49 million for the quarter ending December 31, 2023, a -97.50% decline year-over-year.

Vir Biotechnology Inc (VIR) Net Income 2024

VIR net income (TTM) was -$615.06 million for the quarter ending December 31, 2023, a -219.24% decrease year-over-year.

Vir Biotechnology Inc (VIR) Cash Flow 2024

VIR recorded a free cash flow (TTM) of -$800.36 million for the quarter ending December 31, 2023, a -150.17% decrease year-over-year.

Vir Biotechnology Inc (VIR) Earnings per Share 2024

VIR earnings per share (TTM) was -$4.59 for the quarter ending December 31, 2023, a -220.47% decline year-over-year.

Vir Biotechnology Inc Stock (VIR) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
HANLY ANN M.	EVP & Chief Technology Officer	Apr 01 '24	Sale	10.05	2,711	27,251	132,069
Lee Sung	EVP & Chief Financial Officer	Mar 27 '24	Sale	9.89	6,008	59,404	100,492
SCANGOS GEORGE A	Director	Feb 26 '24	Sale	11.65	17,722	206,522	112,989
Pang Phillip	EVP & Chief Medical Officer	Feb 22 '24	Sale	10.05	14,568	146,344	250,111
HANLY ANN M.	EVP & Chief Technology Officer	Feb 22 '24	Sale	10.05	12,296	123,521	134,780
SCANGOS GEORGE A	Director	Feb 22 '24	Sale	10.05	10,028	100,737	130,711
SCANGOS GEORGE A	Director	Feb 20 '24	Sale	10.22	16,872	172,385	140,739
SCANGOS GEORGE A	Director	Feb 16 '24	Sale	10.24	10,878	111,386	157,611
Pang Phillip	EVP & Chief Medical Officer	Feb 16 '24	Sale	10.24	3,321	34,006	264,679
Pang Phillip	EVP & Chief Medical Officer	Jan 02 '24	Option Exercise	1.38	80,000	110,299	268,000

Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.